BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 61st American Society of Hematology Annual Meeting
Nov 06, 2019 9:00 AM
Oral Presentations:
Title: | Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the SEQUOIA (BGB-3111-304) Trial |
Publication #: | 499 |
Session #: | 642 |
Date: | |
Time: | |
Location: | |
Presenter: |
Title: | Treatment with the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial |
Publication #: | 500 |
Session #: | 642 |
Date: | |
Time: | |
Location: | |
Presenter: |
Poster Presentations:
Title: | An Update on Safety and Preliminary Efficacy of Highly Specific BTK Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies |
Publication #: | 1594 |
Session #: | 626 |
Date: | |
Time: | 5:30 – |
Location: | |
Presenter: |
Title: | A Quantitative Systems Pharmacology (QSP) Model to Predict Receptor Occupancy of BTK Inhibitors in Peripheral Blood Mononuclear Cells, Bone Marrow and Lymph Nodes of Patients with B-Cell Malignancies |
Publication #: | 1289 |
Session #: | 605 |
Date: | |
Time: | 5:30 – |
Location: | |
Presenter: | |
About
Investor Contact | Media Contact |
+1 857-302-5189 | +1 857-302-5663 |
ir@beigene.com | media@beigene.com |
1 ABRAXANE®, REVLIMID® and VIDAZA® are registered trademarks of Celgene Corporation.
Source: